Verastem, Inc. (VSTM) SEC Filings & Earnings Calls

Equity dilution risk from the offering of shares and pre-funded warrants.

“Filing includes an underwriting agreement and pre-funded warrant form, indicating a public equity offering.”

CEO transition risk during early commercial stage

“CEO retiring effective Jan 1, 2027; new CEO appointed but compensation not yet finalized”

Revenue Notes create ongoing royalty obligation on product sales, potentially dilutive to future cash flows

“Revenue Notes entitle Purchasers to quarterly Revenue Payments equal to Revenue Payment Percentage of net sales of avutometinib and defactinib”

Contingent make-whole payment risk if sales milestones not met by 2031

“If Test Date Condition is not satisfied... Purchasers will be entitled to a one-time contingent make-whole payment... equal to 100% of the Funded Amount less total Revenue Payments”

Secured by substantially all assets including IP, increasing creditor control

“Company's obligations... continue to be secured by a first-priority security interest... on substantially all of the Company's and its subsidiaries' assets, including its intellectual property”

Going concern risk

“the significant increase in costs we now expect to incur raises substantial doubt about our ability to continue as a going concern within the twelve months after the date of the issuance of these condensed consolidated financial statements.” · word for word

Dependence on VS-7375 clinical success

“The Company also cleared multiple dose levels in combination with cetuximab with no DLTs. The Company completed targeted enrollment in patients with pancreatic and lung cancer monotherapy cohorts and the colorectal cancer combination cohort with cetuximab in the Phase 1/2 study.” · word for word

Limited product revenue diversification

“We market AVMAPKI FAKZYNJA CO-PACK (avutometinib capsules; defactinib tablets) in the United States (“U.S.”), the first treatment specifically FDA-approved for adults with KRAS-mutated LGSOC who have received prior systemic therapy.” · word for word

Clinical trial and regulatory risks for pipeline programs.

“Pipeline dependency on VS-7375 clinical trials; regulatory paths for LGSOC expansion in Europe and Japan.”

Early-stage data; efficacy and safety need confirmation in larger trials.

“Phase 1/2 trial; limited follow-up in some cohorts.”

Early-stage data with small sample size (29 patients); survival data still maturing; pancreatic cancer remains difficult to treat

“29 patients enrolled; follow-up continues and survival data continue to mature”

Presentation contains extensive forward-looking statements and risk factors; no new material information.

“Forward-looking statements section with standard risk factors”

Going Concern Risk

“Consequently, the significant increase in costs we now expect to incur raises substantial doubt about our ability to continue as a going concern within the twelve months after the date of the issuance of these consolidated financial statements.” · word for word

Dependence on Additional Financing

“If we fail to obtain additional capital or generate sufficient revenue from our commercialization activities in the future, we may be unable to complete our planned preclinical studies and clinical trials and obtain approval of certain investigational product candidates from the FDA or foreign regulatory authorities.” · word for word

Cash Runway Risk

“We expect our existing cash resources including proceeds from exercise of warrants in January 2026, along with revenue we expect to generate from sales of AVMAPKI FAKZYNJA CO-PACK, will be sufficient to fund our planned operations through 12 months from the date of issuance of these consolidated financial statements.” · word for word

Dependence on Single Product

“Product revenue, net, is recognized when earned on gross sales of AVMAPKI FAKZYNJA CO-PACK in the U.S.” · word for word

Clinical Trial Risk

“We are also conducting RAMP 301, a Phase 3 trial designed to evaluate avutometinib plus defactinib versus Investigator’s Choice of Treatment (“ICT”) in patients with recurrent LGSOC with and without a KRAS mutation.” · word for word

Dependence on successful commercial launch and pipeline advancement for sustained growth.

“Given the growth trajectory of the AVMAPKI FAKZYNJA CO-PACK, Verastem anticipates the LGSOC commercial launch and development program will be self-sustaining by the second half of 2026.” · word for word

Discontinuation of RAMP 203 trial; pipeline risk and competitive pressure from next-generation G12C inhibitors.

“next generation G12C inhibitors are establishing a new benchmark with higher response rates” · word for word

COO departure may cause operational disruption; clinical trial risk remains.

“Matthew Ros, chief operating officer, will be departing from the organization as the Company streamlines its operational structure.” · word for word

Dilution risk from equity offering; pre-funded warrants may further dilute.

“Form of Pre-Funded Warrant included in exhibits.”

Dependence on successful commercialization of AVMAPKI FAKZYNJA CO-PACK and clinical trial outcomes for VS-7375.

“Revenue is from a single product launch; pipeline is early-stage with no approved products beyond LGSOC.”

Cash runway only into H2 2026, requiring additional financing or revenue growth.

“Cash runway would extend into the second half of 2026, contingent on product revenue and warrant exercise.” · word for word

Going concern risk

“these conditions raise substantial doubt about our ability to continue as a going concern for 12 months after the date the condensed consolidated financial statements are issued.” · word for word

Dependence on confirmatory trial for full approval

“Continued approval for this indication is contingent upon verification and description of clinical benefit in a confirmatory trial.” · word for word